Publication | Closed Access

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

Diabetes ManagementOnce-weekly Semaglutide 2·0MedicineDiabetesClinical TrialsType 2Sustain FortePharmacotherapyDiabetes ComplicationsDiabetes MellitusPharmacology